Weight-loss medications explained: what is FDA approved for weight and what is not, how each class works, injections vs pills, results, dated prices and the pipeline.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- Prescription weight-management medicines are generally considered for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.[1]
- After one year, adults taking a weight-management medicine with a lifestyle program lose 3% to 12% more of their starting weight than with the program alone.[1]
- Ozempic and Mounjaro are FDA approved for type 2 diabetes, not weight management; Wegovy and Zepbound are the weight brands of the same molecules.[12]
- Two GLP-1 pills are FDA approved for weight in adults: the Wegovy pill (semaglutide) and Foundayo (orforglipron).[4]
- People will probably regain some weight after stopping a weight-management medicine, the NIH notes.[1]
In short: As of October 6, 2026, the FDA has approved several prescription medicines for long-term weight management in adults, including weekly injections (Wegovy, Zepbound), a daily injection (Saxenda), daily pills (the Wegovy pill, Foundayo, Qsymia, Contrave and Xenical) and Imcivree for certain rare genetic conditions, plus phentermine for short-term use and Alli over the counter. Other well-known names, such as Ozempic and Mounjaro, are approved for type 2 diabetes, not for weight management. Medicines are used together with eating and activity changes, and whether one fits a person is a decision for that person and their clinician.
This hub explains what each badge on our medication pages means, which medicines are approved for what, how the classes differ, and what they cost, with every status checked on the current FDA label. It is education, not medical advice.
Start here: do these next 1-2-3
- Learn the label language. According to the NIH, prescription weight-management medicines are generally considered for adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes. Our BMI calculator shows where you stand; it is not a diagnosis.
- Read about the class most people ask about. Our GLP-1 guide explains how Wegovy, Zepbound and the new pills work.
- Bring questions to a clinician. A primary care doctor or an obesity medicine specialist can review your history; our medical weight loss guide explains what a visit includes.
What the status badges mean
Every medication page on InstaTuck shows a status badge taken from the FDA label on DailyMed or an FDA page, with the date we checked it. The ones you will see most often:
- FDA approved for weight management: the label includes chronic weight management (or weight reduction) as an approved use.
- FDA approved for another indication: approved, but for something else, such as type 2 diabetes. Using it for weight would be “off label,” a decision only a prescriber can make.
- Investigational: still in clinical trials and not approved for any use.
- Compounded (not FDA approved): pharmacy-made versions, which the FDA does not review for safety, effectiveness or quality before sale.
- Dietary supplement (not FDA approved): products sold as supplements, which do not go through FDA approval for weight loss.
The full list is on status badges explained.
Approved for weight management
| Medicine | Active ingredient | How it is taken | Labeled for (in general terms) |
|---|---|---|---|
| Wegovy injection | Semaglutide (GLP-1) | Weekly injection | Adults with obesity, or overweight with a weight-related condition; teens 12+ with obesity |
| Wegovy pill | Semaglutide (GLP-1) | Daily tablet, empty stomach | Adults |
| Zepbound | Tirzepatide (GIP/GLP-1) | Weekly injection | Adults; also obstructive sleep apnea in adults with obesity |
| Foundayo | Orforglipron (GLP-1) | Daily tablet, with or without food | Adults |
| Saxenda | Liraglutide (GLP-1) | Daily injection | Adults; children 12+ with obesity and body weight over 60 kg |
| Qsymia | Phentermine and topiramate | Daily capsule | Adults; children 12+ with obesity |
| Contrave | Naltrexone and bupropion | Extended-release tablets | Adults |
| Xenical (orlistat) | Orlistat | Capsule with meals | People with obesity, or a BMI of 27+ with other risk factors |
| Alli (over the counter) | Orlistat, lower strength | Capsule with meals | Overweight adults 18+ with a reduced-calorie, low-fat diet |
| Imcivree | Setmelanotide (MC4R agonist) | Daily injection | Only specific rare genetic and hypothalamic forms of obesity |
| Phentermine | Phentermine | Tablet or capsule | Short-term use (a few weeks) only |
A few label details are worth knowing. Qsymia and phentermine are controlled substances (Schedule IV). Contrave carries a boxed warning about suicidal thoughts and behaviors because it contains bupropion, an antidepressant ingredient. The GLP-1 injections carry a boxed warning about thyroid C-cell tumors seen in rodents. Each medication page lists its own warnings, side effects and who should not use it.
Approved for other uses, not for weight
Some of the most searched names are diabetes medicines. Ozempic and Rybelsus contain semaglutide and are approved for type 2 diabetes; Mounjaro contains tirzepatide and is approved for type 2 diabetes. Victoza (liraglutide) and Trulicity (dulaglutide) are also type 2 diabetes medicines. They can lower weight, but weight management is not on their labels. When the same molecule is approved for weight under another name, our pages say so: Wegovy for semaglutide, Zepbound for tirzepatide and Saxenda for liraglutide. Our guide to Ozempic for weight loss explains the off-label question.
By class: how they work
- GLP-1 receptor agonists (semaglutide, liraglutide, orforglipron) mimic a gut hormone that slows stomach emptying and signals fullness to the brain. See the GLP-1 guide.
- Dual GIP/GLP-1 receptor agonist (tirzepatide) acts on two gut-hormone receptors. Compare the two main molecules in semaglutide vs tirzepatide.
- Appetite-suppressant combinations: phentermine is a sympathomimetic amine; Qsymia pairs it with topiramate; Contrave pairs naltrexone, an opioid antagonist, with bupropion. See appetite suppressants.
- Lipase inhibitor (orlistat) reduces how much dietary fat the gut absorbs.
- MC4R agonist (setmelanotide) is for specific rare genetic conditions confirmed by testing, and for acquired hypothalamic obesity.
Injection or pill?
Two daily GLP-1 pills are now approved for weight management: the Wegovy pill (December 2025) and Foundayo (April 2026). They differ in their rules: the Wegovy pill is taken on an empty stomach with a small amount of water and a wait before eating, while Foundayo can be taken with or without food. Injections are weekly (Wegovy, Zepbound) or daily (Saxenda). The digestive side effects come from how the medicine works, so they occur with pills as well. Our weight-loss injections hub and weight-loss pills hub go deeper, and Wegovy vs Zepbound compares the two weekly injections.
What results to expect
The NIH summarizes that after one year, adults taking a prescription weight-management medicine as part of a lifestyle program lose 3% to 12% more of their starting weight than people in a lifestyle program alone, and notes that a loss of 5% to 10% may already improve health. Results vary by medicine and by person; each medication page reports its main trials as published. The NIH also notes that people will probably regain some weight after stopping, and that healthy eating and activity help limit regain. Our life after a GLP-1 guide covers that stage.
Cost and coverage
The NIH notes that some, but not all, insurance plans cover these medicines. Prices change often, so we show them only with the date we checked them on the manufacturer’s site. As of October 6, 2026, Wegovy pens were $349 a month self-pay through NovoCare Pharmacy and Wegovy pills $149 to $299; Zepbound KwikPens were $299 to $449 through Lilly; Foundayo was $149 to $349 by strength. Medicare’s temporary GLP-1 Bridge (July 2026 through December 2027) covers Wegovy, Zepbound KwikPen and Foundayo for weight management with a $50 copay for people who meet its criteria. See Wegovy cost, Zepbound cost, the GLP-1 cost comparison and our GLP-1 coverage guide.
Compounded and “research” versions of semaglutide and tirzepatide are not FDA approved; see compounded GLP-1s before considering one.
All medications, with filters
Filter by status, class and route (injection or pill). Only pages that have passed medical review appear here.
20 results
FDA approved for weight managementOver the counterPillAlli (orlistat 60 mg): the over-the-counter weight-loss pillOrlistat (Xenical and Alli): how the fat-blocker works · Capsule · Daily
FDA approved for weight managementPrescriptionPillContrave (naltrexone/bupropion): how it works and its warningsPill (tablet) · Daily
FDA approved for weight managementPrescriptionPillFoundayo (orforglipron): status, uses and what is confirmedOrforglipron: the small-molecule GLP-1 pill and its current status · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionImcivree (setmelanotide): for specific rare genetic causes of obesityInjection · Daily
FDA approved for weight managementPrescriptionInjectionLiraglutide: the daily GLP-1 (Saxenda, Victoza) and genericsInjection · Daily
FDA approved for another usePrescriptionInjectionMounjaro (tirzepatide): approved uses and how it differs from ZepboundTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · Weekly
FDA approved for weight managementPrescriptionPillOrforglipron: the small-molecule GLP-1 pill and its current statusPill (tablet) · Daily
FDA approved for weight managementPrescriptionPillOrlistat (Xenical and Alli): how the fat-blocker worksCapsule · Daily
FDA approved for another usePrescriptionInjectionOzempic (semaglutide): approved uses and how it differs from WegovySemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionPillPhentermine: short-term weight-loss pill, risks and rulesPill (tablet) · Daily
FDA approved for weight managementPrescriptionPillQsymia (phentermine/topiramate): uses, risks and REMSCapsule · Daily
Investigational: not FDA approvedPrescriptionInjectionRetatrutide: an investigational triple agonist (not FDA approved)Injection · Weekly
FDA approved for another useOff-label use discussedPrescriptionPillRybelsus (oral semaglutide): a diabetes pill, not a weight-loss approvalSemaglutide: one ingredient, several brands · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionSaxenda (liraglutide 3 mg): uses, side effects and costLiraglutide: the daily GLP-1 (Saxenda, Victoza) and generics · Injection · Daily
FDA approved for weight managementPrescriptionInjectionSemaglutide: one ingredient, several brandsInjection · Daily, Weekly
FDA approved for weight managementPrescriptionInjectionTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro)Injection · Weekly
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionWegovy HD (semaglutide 7.2 mg): what the higher dose is, results and statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionPillWegovy Pill (oral semaglutide): status, how it is taken, how it comparesSemaglutide: one ingredient, several brands · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · WeeklyBadges come from the FDA label or FDA records and show the date we last checked. Listing order is never paid for.
Emerging medications
New weight-management medicines continue to be studied in clinical trials. Investigational medicines are not approved and are always labeled that way here, with their status taken only from FDA records and ClinicalTrials.gov. Our emerging medications page tracks the pipeline, including retatrutide, and the research section reports new approvals as they happen.
In this section
Emerging Weight-Loss Medications: the pipeline, with honest status labelsEmerging weight-loss medications: a dated pipeline table of retatrutide, CagriSema, zenagamtide, MariTide, survodutide, eloralintide and more,…
GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…Related guides
Medical Weight Loss: physician-supervised options explainedMedical weight loss explained: who provides it, what a visit and labs include, programs, medications, procedures,…GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…
Weight-Loss Injections: GLP-1 and dual-agonist shots explainedWeight-loss injections explained: which shots are FDA approved for weight vs diabetes, weekly vs daily, using…
Weight-Loss Pills: prescription, over-the-counter and supplements, by evidenceWeight-loss pills by evidence: FDA-approved prescription pills (Wegovy pill, Foundayo, Qsymia, Contrave, orlistat, phentermine), Alli over…Tools for this topic
Latest research
How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…
What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…
Fake and Counterfeit Weight-Loss Drugs: How to Spot ThemCounterfeit Ozempic has reached U.S. pharmacies three times. The FDA alerts, what online test buys found,…Questions to ask a professional
- Based on my health history, which medication classes could be appropriate, and which should I avoid?
- Do any of my current medicines or conditions affect my options?
- What results and side effects are realistic for me with each option?
- What would each option cost me with my insurance, or without it?
- How long would I take it, and what is the plan if I stop?
Frequently asked questions
Which weight-loss medications are FDA approved?
As of 2026-10-06: Wegovy (injection and pill), Zepbound, Foundayo, Saxenda, Qsymia, Contrave, Xenical and over-the-counter Alli for long-term weight management, Imcivree for specific rare genetic and hypothalamic obesity, and phentermine for short-term use. Each label defines who it is for.
Is Ozempic approved for weight loss?
No. Ozempic is approved for type 2 diabetes and related heart and kidney outcomes. Wegovy contains the same active ingredient, semaglutide, and is approved for chronic weight management.
Is there a weight-loss pill that works like the injections?
Yes. The Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026) are daily GLP-1 pills approved for weight management in adults.
Who can take weight-loss medication?
Labels generally cover adults with obesity, or overweight with at least one weight-related condition; some are also approved for teens. A clinician decides whether a medicine fits a particular person after reviewing their health history.
Do I have to take these medicines forever?
They are labeled for long-term use, and trials show weight tends to return after stopping. Any change should be planned with the prescriber, together with eating, activity and follow-up.
References
- Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 7, 2026) Government page
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- SAXENDA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- QSYMIA (phentermine and topiramate) extended-release capsules: prescribing information. Vivus, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets: prescribing information. Nalpropion Pharmaceuticals, via DailyMed, 2025. (accessed October 6, 2026) Drug label
- XENICAL (orlistat) capsules: prescribing information. H2-Pharma / CHEPLAPHARM, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- ALLI (orlistat 60 mg) capsules: Drug Facts. Haleon, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- IMCIVREE (setmelanotide) injection: prescribing information. Rhythm Pharmaceuticals, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- Phentermine hydrochloride tablets: prescribing information. Via DailyMed (generic labeler), 2026. (accessed October 6, 2026) Drug label
- OZEMPIC (semaglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- MOUNJARO (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- VICTOZA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed. (accessed October 6, 2026) Drug label
- TRULICITY (dulaglutide) injection: prescribing information. Eli Lilly and Company, via DailyMed. (accessed October 6, 2026) Drug label
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.